CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Rebounding biotech funds expected to spur CDMO growth within year

Positive
AI Analysis

Summary

Analysts expect contract development and manufacturing organizations (CDMOs) to experience increased demand in late 2026 or early 2027 as biotech funding rebounds, with pharma services historically lagging changes in biotech investment cycles.

Importance:3/10
Sentiment:
0.40
CDMObiotech fundingpharma servicesmarket outlook

Read the original article

Published by BioSpace on August 18, 2026 12:37 PM

Read Original